ResultsIQ

ResultsIQ › Latest results › Gufic Biosciences Limited

Gufic Biosciences Limited Q2 FY26 results deck summary

NSE: GUFICBIO · BSE: 509079

Results deck of 14 Nov 2025, summarised by AI from the filing.

Q2 FY26 revenue ₹230.4 cr with EBITDA margin 16.45%; Indore facility on track for 30% utilization and EBITDA breakeven in FY26.

Key takeaways

  1. Q2 FY26 revenue Total revenue ₹230.4 cr (Q2 FY25: ₹204.2 cr); PAT ₹14.9 cr (Q2 FY25: ₹21.8 cr).
  2. Indore guidance 30% capacity utilization and EBITDA breakeven at Indore targeted for FY26; margin accretive from FY27.
  3. Margin change EBITDA margin fell to 16.45% in Q2 FY26 from 18.95% in Q2 FY25.
  4. Growth driver Hospital injectable platform expansion with Jan’26 Contrast Media and Apr’26 TPN launches.
  5. Risk Indore product permissions from State FDA ongoing; 145 approvals received, more in pipeline.

Original filing on BSE

Gufic Biosciences Limited Q1 FY27 results

As filed: Revenue ₹261 cr (+16% year on year), EBITDA ₹46.6 cr (+41% year on year), PAT ₹22.3 cr (+72% year on year), EBITDA margin 17.9% (+314 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹252 cr (+23% year on year), EBITDA ₹47.2 cr (+75% year on year), PAT ₹21.9 cr (+174% year on year), EBITDA margin 18.8% (+558 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 558 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +8.3% in 27 days (Nifty 500: +2.0%).
  • Q3 FY26: Revenue ₹231 cr (+11% year on year), EBITDA ₹33.0 cr (−3% year on year), PAT ₹12.4 cr (−35% year on year), EBITDA margin 14.3% (−209 bps). Score 46 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 209 bps year on year. Profit fell 27% from last quarter. Share price after the results: −7.1% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹237 cr (+16% year on year), EBITDA ₹39.0 cr (+3% year on year), PAT ₹17.0 cr (−23% year on year), EBITDA margin 16.5% (−217 bps). Score 60 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin fell 217 bps year on year. Share price after the results: +9.4% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹224 cr (+10% year on year), EBITDA ₹33.0 cr (−8% year on year), PAT ₹13.0 cr (−38% year on year), EBITDA margin 14.7% (−300 bps). Score 26 of 100, Below trend. EBITDA margin fell 300 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +3.5% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹205 cr (+5% year on year), EBITDA ₹27.0 cr (−21% year on year), PAT ₹8.0 cr (−60% year on year), EBITDA margin 13.2% (−427 bps). Score 17 of 100, Below trend. EBITDA margin fell 427 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 58% from last quarter. Share price after the results: −10.7% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹208 cr (+3% year on year), EBITDA ₹34.0 cr (−8% year on year), PAT ₹19.0 cr (−14% year on year), EBITDA margin 16.4% (−197 bps). Score 25 of 100, Below trend. EBITDA margin fell 197 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 14% from last quarter.
  • Q2 FY25: Revenue ₹204 cr (−5% year on year), EBITDA ₹38.0 cr (−3% year on year), PAT ₹22.0 cr (−4% year on year), EBITDA margin 18.6% (+49 bps). Score 29 of 100, Below trend. EBITDA margin rose 49 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Gufic Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.